GovChime
Notice ID: 60c6fdeb7763436d9e2ac65227d95af1Presolicitation

Sirturo (Bedaquiline) tablets for the NIH (Notice of Intent to sole source)

Responses closed . Full description on SAM.gov.

Overview

Response deadline
4:00 PM EST
Posted
November 6, 2026
Notice type
Presolicitation
NAICS
325412: Pharmaceutical Preparation Manufacturing
Agency
Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH

Notice details

Office
NATIONAL INSTITUTES OF HEALTH - CC
Place of performance
Bethesda, Maryland, 20814
Last updated
Nov 6, 2026
First published
Last updated on SAM.gov

Identifiers

Solicitation number
NOI-27-000056
Notice ID
60c6fdeb7763436d9e2ac65227d95af1

Description

Acquisition Description:

This is a Notice of Intent, not a request for proposal.  The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with Cardinal Health. This requirement will be sole sourced to Cardinal Health under FAR 13.501(a) or 8.405-6 (b) - sole source requirements.

The National Institutes of Health (NIH) Clinical Center (CC) (NIH-CC or “Program”) is a clinical research hospital providing all medical services for patients participating in human research protocols of the NIH. The CC Pharmacy department provides a range of pharmaceutical care services to inpatients and outpatients enrolled in clinical trials. The CC Pharmacy department is responsible for acquiring the supply of medications required for patient care. The NIH-CC has a pharmacy center that requires Sirturo (Bedaquiline) drug tablets for patient care. Sirturo is supplied in the following forms: 100 mg tablets in 188 count bottles and 20 mg tablets in 60 count bottles. Various different quantities are needed every year. Based on Program’s purchase history in the past, and factoring in the anticipated patient enrollment, Program expects to need approximately 12 - 36 bottles of each type of Sirturo® bottles per year.

Justification:

Only this Sirturo medication can be accepted as there are no substitutes for this medication. The manufacturer (Janssen Therapeutics) has designated Cardinal Health (DBA Metro Medical Supply) as the sole distributor of Sirturo in the U.S.

Previous acquisitions and research indicated that this requirement should be a sole source requirement. For the previous acquisitions, Notice of Intent notices were posted on SAM.gov.  Cardinal Health/Metro Medical was the only sole source provider. In order to confirm this is still applicable, this requirement was previously posted on SAM.gov as an RFQ under full and open competition under RFQ-CC-24-008485. No other companies responded, and it was confirmed by this posting that they are the sole source vendor. Previous acquisitions and research revealed this requirement should be a sole source requirement. More recently, a Request for Quotes was posted under RFQ-CC-24-008485 and it was reconfirmed that Cardinal Health/Metro Medical is the sole source vendor as they are the official authorized reseller of this equipment via their relationship with the manufacturer. Thus, Cardinal Health/Metro Medical is the only responsible and authorized source for Sirturo.

Requirements:

SIRTURO (BEDAQUILINE) 100 mg tablet in 188-count bottles (NDC# 59676070101)

SIRTURO (BEDAQUILINE) 20 mg tablet in 60-count bottles (NDC#59676070260)

Period of performance/Date of Delivery:

Within 30 days of award, or mutually agreed upon.

Place of Performance or Delivery:

Place of Performance: NIH Clinical Center in Bethesda, MD

The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL.  All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-27-000056) by 04:00 PM eastern standard time on 11/11/2026 to: lu-chang.lu@nih.gov

All responses received by the closing date of this synopsis will be considered by the Government.  A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Contracting Officer

Primary Contact

Documents

No documents available.

Lifecycle

  1. 1
    Version 1PresolicitationCurrent

    Sirturo (Bedaquiline) tablets for the NIH (Notice of Intent to sole source)

    Notice 60c6fdeb7763436d9e2ac65227d95af1 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
Valsartan Tablets Solicitation SPE2D2-26-R-0011
72%
Solicitation07/23/2026
71%
AwardedOpen
SPE2D2-26-R-0012 Febuxostat Tablets Solicitation
71%
Solicitation10/15/2026
Amendments was issued to update the schedule of supplies. See attached updated schedule of supplies / pricing sheet for more details.
71%
Pre-Solicitation08/26/2026
PRE-SOLICITATION NOTICE: The VA National Acquisition Center intends to issue Request for Proposal (RFP) 36E79726R0032 for an unrestricted procurement for Lisinopril Tablets, for the Department of Veterans Affairs (VA) (inclusive of Consolidated Mail Order Pharmacies (CMOPs) and Option 2 State Veterans Homes (SVH)), Department of Defense (DoD) (inclusive of Tricare Mail Order Pharmacies (TMOPs)), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC). VA will award one contract to the responsible offeror who will be able to provide an uninterrupted source of supply for the contracted item. The contract period will be for one year plus four pre-priced one-year option periods. The contract items will be distributed through the VA s and DOD s respective Pharmaceutical Prime Vendor Programs. Offerors must state the exact name (name that appears on label) by which the drug will be supplied and have an NDC number that is unique to the offeror. The successful offeror/contractor's label with its unique NDC shall be the only label on the product. Contractors shall not affix their label over another label on the product. VA labels must be able to securely adhere on top of the successful offeror/contractor s label. All unit of use packaging identified in the Schedule of Supplies, (Line items 3, 4, 7, 8, 11, 12, 14, 18, 19, and 31 for 45 and 90 count bottles) shall contain a safety-cap capable of having the outer part of the cap deshelled and / or a convertible cap to produce a non-safety cap and a bottle with a minimum required size of 120cc volume. The safety cap must not exceed the diameter of the bottle. The bottle must have a cylindrical body and minimum of 5.75 circumference. The bottle must fit a label with a dimension of 5.25 x 2 . The 0.5 additional space is required to keep the bar code exposed and/or allow for the display of the expiration date and lot number. Solicitation # 36E79726R0032 will be electronically issued in commercial item format in accordance with FAR Part 12 on or about September 3, 2026 with a tentative closing date of September 24, 2026 The NAICS code for this procurement is 325412. Any future amendments and other miscellaneous documents will be available electronically for download at sam.gov. No paper copies of the solicitation will be available, and no telephone requests for paper copies of the solicitation will be accepted. Interested offerors are advised to continuously check Contracting Opportunities at SAM.gov for any changes to this solicitation. All responsible sources may submit an offer that if timely received, will be considered. The point of contact for this procurement is Youlanda Duggar. Questions can be e-mailed to Youlanda.Duggar@va.gov. Please see the Excel spreadsheet for estimated annual quantities.
71%
Pre-Solicitation09/24/2026

Additional Details

Solicitation Number

NOI-27-000056

Archive Date

Nov 26, 2026

Office Address

BETHESDA, MD, 20892